Literature DB >> 25002729

Reply to H. Kantarjian et al.

Rüdiger Hehlmann, Joerg Hasford, Markus Pfirrmann, Michael Lauseker, Susanne Saußele, Andreas Hochhaus.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25002729     DOI： 10.1200/JCO.2014.56.3908

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  2 in total

Review 1.  Chronic Myeloid Leukemia: Beyond BCR-ABL1.

Authors:  Ting Zhou; L Jeffrey Medeiros; Shimin Hu
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

2.  Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemia.

Authors:  Z Chen; L J Medeiros; H M Kantajian; L Zheng; Z Gong; K P Patel; H Xiong; W Wang; J E Cortes; S Hu
Journal:  Blood Cancer J       Date:  2017-02-03       Impact factor: 11.037
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.